Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Precision medicine enabled histology agnostic development of immunotherapeutics

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 1973

Dr Roy Baynes - Merck Research Laboratories, Rahway, USA

Prof Baynes speaks with ecancer at WIN 2017 about design and development of immune therapies sensitive to mutational deficiencies in the DNA repair pathway

He notes the recent approval of pembrolizumab (Keytruda) PD1 therapy for relapsed cancer patients with a high mutational burden determined with a micro-satellite instability assay.

Prof Baynes outlines the ongoing trials combining checkpoint immunotherapy with targeted agents such as tyrosine kinases, radiotherapy and chemotherapy, including results alongside other immuno-modulatory agents such as oncolytic viruses.

Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation